<abstract xmlns="http://www.w3.org/1999/xhtml"> Background: Chronic hepatitis C is a common cause of advanced liver disease and appropriate treatment has been complex and a challenge. Reaction of individual genotypes to classical pegylated interferon-ribavirin therapy differs and no success has been achieved in some even after repeated therapy cycles. New types of so called directly acting antivirals (DAAs) are hopeful, as shown in many recent clinical studies, and triple therapy regimens involving DAA are becoming the new standard of care.Objective: To summarize knowledge about the relationship between HCV therapeutic regimens and the genetic background of the host represented by interleukin 28B (IL28B) gene polymorphisms. In the first part, the host basic mechanisms in specific and innate immunity are introduced. The IL28B genotype and its role in the course of HCV treatment are described in the second part.Methods: We searched and summarized publications on HCV therapeutic regimens and host IL28B polymorphisms.Results: Compared to classical regimens, the association between IL28B polymorphism and treatment outcome of HCV infected patients is weaker in triple therapy using first generation DAAs boceprevir and telaprevir.Conclusions: The association between IL28B polymorphism and treatment outcome is lessened with availability of new therapeutic regimens. Nevertheless, IL28B genotyping may still be useful for individualization of treatment strategies.</abstract>

Background: Chronic hepatitis C is a common cause of advanced liver disease and appropriate treatment has been complex and a challenge. Reaction of individual genotypes to classical pegylated interferon-ribavirin therapy differs and no success has been achieved in some even after repeated therapy cycles. New types of so called directly acting antivirals (DAAs) are hopeful, as shown in many recent clinical studies, and triple therapy regimens involving DAA are becoming the new standard of care.Objective: To summarize knowledge about the relationship between HCV therapeutic regimens and the genetic background of the host represented by interleukin 28B (IL28B) gene polymorphisms. In the first part, the host basic mechanisms in specific and innate immunity are introduced. The IL28B genotype and its role in the course of HCV treatment are described in the second part.Methods: We searched and summarized publications on HCV therapeutic regimens and host IL28B polymorphisms.Results: Compared to classical regimens, the association between IL28B polymorphism and treatment outcome of HCV infected patients is weaker in triple therapy using first generation DAAs boceprevir and telaprevir.Conclusions: The association between IL28B polymorphism and treatment outcome is lessened with availability of new therapeutic regimens. Nevertheless, IL28B genotyping may still be useful for individualization of treatment strategies.

IL28B genotyping and treatment of HCV infected subjects

PhD, Department of Clinical Biochemistry, University Hospital Olomouc, 77520 Olomouc,

Department of Clinical Biochemistry, University Hospital Olomouc, Olomouc 77520,

Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc 77520,

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"IL28B genotyping and treatment of HCV infected subjects"}

Background: Chronic hepatitis C is a common cause of advanced liver disease and appropriate treatment has been complex and a challenge. Reaction of individual...

IL28B genotyping and treatment of HCV infected subjects

Article Category: Review article

Pubblicato online: 04 feb 2017

Pagine: 445 - 452

DOI: https://doi.org/10.5372/1905-7415.0804.313

Parole chiave
Chronic hepatitis C, direct acting antiviral, genotyping, hepatitis C virus, IL28B polymorphism, sustained virological response

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

IL28B genotyping and treatment of HCV infected subjects

Article Category: Review article

Pubblicato online: 04 feb 2017

Pagine: 445 - 452

DOI: https://doi.org/10.5372/1905-7415.0804.313

Parole chiaveChronic hepatitis C, direct acting antiviral, genotyping, hepatitis C virus, IL28B polymorphism, sustained virological response

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Parole chiave
Chronic hepatitis C, direct acting antiviral, genotyping, hepatitis C virus, IL28B polymorphism, sustained virological response